TY  - CONF
AU  - Rodríguez-Baz, Íñigo
AU  - Bernhardt, Alexander M
AU  - Aldecoa, Iban
AU  - Arranz, Javier
AU  - Arriola-Infante, José Enrique
AU  - Maure-Blesa, Lucía
AU  - Carmona-Iragui, Maria
AU  - Longen, Sebastian
AU  - Trossbach, Svenja Verena
AU  - Giese, Armin
AU  - Matthias, Torsten
AU  - Benejam, Bessy
AU  - Videla, Laura
AU  - Hoyo, Laura Del
AU  - Barroeta, Isabel
AU  - Hernandez, Aida Sanjuan
AU  - Fernandez, Susana
AU  - Vaqué-Alcázar, Lídia
AU  - Aranha, Mateus Rozalem
AU  - Morcillo-Nieto, Alejandra O
AU  - Nübling, Georg
AU  - Wagemann, Olivia
AU  - Stockbauer, Anna
AU  - Tondo, Mireia
AU  - Bejanin, Alexandre
AU  - Lleó, Alberto
AU  - Alcolea, Daniel
AU  - Molina, Laura
AU  - Fortea, Juan
AU  - Levin, Johannes
TI  - Alpha-Synuclein Pathology in Down Syndrome-Associated Alzheimer's Disease: Insights from Seed Amplification Assay and Neuropathology
JO  - Alzheimer's and dementia
VL  - 21
IS  - S2
SN  - 1552-5260
M1  - DZNE-2026-00046
SP  - e106390
PY  - 2025
AB  - Down syndrome (DS) is a genetic cause of Alzheimer's disease (AD), with virtually all individuals developing AD pathology by their fourth decade due to Amyloid Precursor Protein (APP) gene overexpression. In addition to amyloid beta (Aβ) plaques and hyperphosphorylated tau (p-Tau) aggregates, DS-associated AD (DSAD) often includes α-synuclein (αSyn) aggregates, contributing to Lewy body pathology (LBP). The αSyn Seed Amplification Assay (SAA) in cerebrospinal fluid (CSF) enables the in vivo detection of misfolded αSyn. While αSyn-SAA has revealed αSyn pathology in autosomal dominant (6
T2  - Alzheimer’s Association International Conference
CY  - 27 Jul 2025 - 31 Jul 2025, Toronto (Canada)
Y2  - 27 Jul 2025 - 31 Jul 2025
M2  - Toronto, Canada
KW  - Humans
KW  - Biomarkers: cerebrospinal fluid
KW  - Male
KW  - Female
KW  - Alzheimer Disease: cerebrospinal fluid
KW  - Alzheimer Disease: pathology
KW  - alpha-Synuclein: cerebrospinal fluid
KW  - Amyloid beta-Peptides: cerebrospinal fluid
KW  - Down Syndrome: cerebrospinal fluid
KW  - Down Syndrome: pathology
KW  - Middle Aged
KW  - tau Proteins: cerebrospinal fluid
KW  - Aged
KW  - Adult
KW  - Neurofilament Proteins: cerebrospinal fluid
KW  - Cohort Studies
KW  - Peptide Fragments: cerebrospinal fluid
KW  - Biomarkers (NLM Chemicals)
KW  - alpha-Synuclein (NLM Chemicals)
KW  - Amyloid beta-Peptides (NLM Chemicals)
KW  - tau Proteins (NLM Chemicals)
KW  - Neurofilament Proteins (NLM Chemicals)
KW  - Peptide Fragments (NLM Chemicals)
LB  - PUB:(DE-HGF)1 ; PUB:(DE-HGF)16
C6  - pmid:41500202
DO  - DOI:10.1002/alz70856_106390
UR  - https://pub.dzne.de/record/283150
ER  -